For laboratory and educational research use only. Not medical advice.
Women's Peptide Research
Ask Vera
Home  /  Database  /  Cerebrolysin
Cognitivephase_2_3

Cerebrolysin

FPF-1070
Cognitive
ASK VERA ABOUT THIS ↗BROWSE THE CATALOG ↗
Category
Cognitive
Evidence grade
B
PubMed records
629
Female-tagged
172
Sex-analysis
0
CAS
—
B
Evidence grade B, Phase 2/3 human trial evidence across 629 indexed studies (mixed-sex). How grades work →
Female evidence: Extrapolated
Cerebrolysin: of 629 PubMed records, 172 are tagged as including female subjects and 0 carry a sex-analysis tag.Counts reflect PubMed records as of 2026-07-21. “Female” uses the Female MeSH filter and “sex-analysis” the Sex Factors MeSH filter, automated proxies pending manual study-level review. Methodology →

Overview

Cerebrolysin is a peptide preparation derived from porcine brain tissue, consisting of a mixture of low-molecular-weight peptides and amino acids. Because it is a defined biological preparation rather than a single molecule, it is used in neuroscience research as a material for studying broad neurotrophic signaling.

In preclinical models Cerebrolysin has been studied for its relationship to neurotrophic pathways, the signaling systems associated with neuronal survival, growth, and plasticity. Researchers examining neurological and neurodegeneration biology have used it as a research material to characterize how such peptide mixtures influence these pathways in cell-based and animal systems.

What makes Cerebrolysin a notable entry for a neurological research catalog is its use as a composite neurotrophic preparation rather than a single-target agent. Whether these mechanisms translate to female physiology remains an open research question; our evidence review tracks how many of the underlying studies included women.

Summary

Cerebrolysin is a porcine-brain-derived peptide preparation used clinically in many countries for stroke, traumatic brain injury, and dementia. It has been tested in numerous trials, though systematic reviews find its benefit uncertain; it is not FDA-approved and its results are rarely analyzed by sex.

Evidence in women

Menstrual cycle
Unstudied
No study examined neurological endpoints across the menstrual cycle.
Pregnancy & lactation
Unstudied
No adequate pregnancy or lactation safety data.
Hormonal interactions
Unstudied
No controlled data on reproductive- or thyroid-hormone interactions.
Perimenopause & menopause
Unstudied
No perimenopause- or menopause-specific analyses, though dementia populations include older women.
Sex differences
Unstudied
Trials enrolled women, but published results were generally not analyzed by sex.

Mechanism

A mixture of low-molecular-weight peptides and amino acids proposed to have neurotrophic and neuroprotective activity.

Reported dosing & routes

◐

We don't give dosing or medical advice. The figures below describe what was used in published research, not a recommendation. Decide with your clinician.

Reported range (literature)Intravenous courses (e.g., ~10–30 mL/day) are used in the countries where it is marketed; investigational in the US.
Routesintravenous
Female-specific dosingNot established

Contraindications: severe kidney impairment; epilepsy (status epilepticus reported rarely)

Side effects

Reported in the research literature. Sex-specific incidence has not been separately analysed in the available records.

injection-site reactionsdizzinessagitation (uncommon)

Cerebrolysin reconstitution calculator

Enter this vial's amount, the bacteriostatic water you add, and a target amount to get the concentration and the U-100 syringe units to draw. Handling arithmetic for research use, not a dose recommendation.

Reconstitution

1
2
3

Draw for Cerebrolysin

5
units on a U-100 insulin syringe
020406080100
U-100 insulin syringe — 1 mL = 100 units
That's 0.05 mL drawn to the 5-unit mark.
Concentration5 mg/mL (5,000 mcg/mL)
Volume to draw0.05 mL
Doses per vial40

Reference chart at 5 mg/mL

Target amountVolume (mL)U-100 units
100 mcg0.02 mL2
250 mcg0.05 mL5
500 mcg0.1 mL10
750 mcg0.15 mL15
1000 mcg0.2 mL20

Research-use arithmetic only. This tool converts a vial amount, diluent volume, and a target amount into a concentration and syringe draw for laboratory handling. It is not dosing guidance, a recommendation, or a claim of safety or efficacy, and it does not account for overfill, dead space, or peptide purity. Nothing here is medical advice. “U-100” means 100 units = 1 mL; confirm your syringe graduation before measuring. See the reconstitution & storage handbook for handling detail.

Frequently asked questions

Answers drawn only from Cerebrolysin's research facts and, where reviewed, its sex-disaggregated evidence. Nothing here is medical advice, dosing, or a claim of safety or efficacy.

What is Cerebrolysin?

Cerebrolysin, also known as FPF-1070, is a research compound in our cognitive category. Cerebrolysin is a porcine-brain-derived peptide preparation used clinically in many countries for stroke, traumatic brain injury, and dementia.

Is Cerebrolysin studied in women?

Cerebrolysin: of 629 PubMed records, 172 are tagged as including female subjects and 0 carry a sex-analysis tag. We grade this extrapolated: women appear in the record, but no study is tagged for a sex-specific analysis, so female-relevant conclusions are inferred from mixed or male data rather than measured in women. See our methodology.

Has Cerebrolysin been studied during pregnancy or breastfeeding?

Unstudied. No adequate pregnancy or lactation safety data. This is not a safety clearance or a recommendation. Vera, our research chat, deliberately hard-stops on pregnancy, breastfeeding, and trying-to-conceive questions rather than answer them.

What evidence grade does Cerebrolysin have, and why?

Cerebrolysin carries evidence grade B. Phase 2/3 human trial evidence across 629 indexed studies (mixed-sex).. Grades are derived from the research record, never hand-assigned; see how grades work.

Is there a female-specific dose for Cerebrolysin?

No. A female-specific dose for Cerebrolysin is not established, and this site does not provide dosing or medical advice. Any figures we show describe what published research used, not a recommendation. Decide anything about use with a qualified clinician.

How is Cerebrolysin administered in research?

In the published literature, Cerebrolysin is administered via intravenous. Reported dose ranges on the Dosing tab describe what studies used for laboratory research, not a protocol for people. We don't provide dosing.

What side effects have been reported for Cerebrolysin?

Effects reported in the research literature include injection-site reactions, dizziness, agitation (uncommon). Sex-specific incidence has not been separately analysed in the available records, so these are not broken out for women.

How should Cerebrolysin be stored and handled?

Cerebrolysin sold for research is supplied as a lyophilized (freeze-dried) powder. Lyophilized peptides are generally kept cold and dry, at roughly -20°C for longer-term storage and 2-8°C short-term, protected from light. Once reconstituted they are typically refrigerated and used within a short window, avoiding repeated freeze-thaw cycles. This is general laboratory handling for research use only, not a directive for human use. Always follow the handling and purity details on the product's Certificate of Analysis.

Where can I buy Cerebrolysin for research?

Cerebrolysin is not currently listed by our research-use partner, Aurevena Research, but their catalog carries related compounds. Code research15 applies 15% off. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.

Browse the Aurevena catalog
Research-use supplier: Cerebrolysin isn't currently listed by our research-use vendor. Their catalog carries related compounds. Code research15 for 15% off, applied automatically at checkout. We may earn a commission when you purchase through this link, at no extra cost to you. Products are for laboratory research use only.
Browse the catalog →

Citations (PMID)

36979317 · 37818733

Related peptides

Arginine VasopressinA
Arginine Vasopressin: of 12,241 PubMed records, 4,072 are tagged as including female subjects and 100 carry a sex-analysis tag.
BromantaneC
Bromantane: of 62 PubMed records, 16 are tagged as including female subjects and 1 carry a sex-analysis tag.
DavunetideB
Davunetide: of 102 PubMed records, 24 are tagged as including female subjects and 4 carry a sex-analysis tag.
DihexaD
Dihexa: of 17 PubMed records, 0 are tagged as including female subjects and 0 carry a sex-analysis tag.

Educational information for laboratory and research use only. Not medical advice, a recommendation, or a claim of safety or efficacy; no personal dosing. “Unstudied” means no qualifying study was found, not that a compound is safe or unsafe.